Related Experiment Video
Updated: Feb 22, 2026
10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
16.4K
Statins and Cognition in Parkinson's Disease
Benjamin L Deck1, Jacqueline Rick1, Sharon X Xie2
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Journal of Parkinson'S Disease
|September 19, 2017
Summary
Statin use in Parkinson's disease (PD) patients was linked to better cognitive function and slower cognitive decline. This study explored the cognitive effects of statins in individuals with PD.
Area of Science:
- Neurology
- Pharmacology
Background:
- The impact of statin medication on cognitive function in Parkinson's disease (PD) remains unclear.
- Understanding this relationship is crucial for managing PD progression.
Purpose of the Study:
- To investigate the association between statin use and cognitive performance in Parkinson's disease patients.
- To examine both cross-sectional and longitudinal cognitive changes in relation to statin use.
Main Methods:
- Collected data from 313 Parkinson's disease participants, including neuropsychological tests, medication records, and functional ability ratings.
- Analyzed cognitive performance at baseline and tracked changes over time.
Main Results:
- Statin users (SU) demonstrated superior performance in global cognition, Trails B, semantic fluency, and phonemic fluency compared to non-statin users (NSU).
- A significantly slower rate of long-term global cognitive decline was observed in SU, assessed using the Dementia Rating Scale-2 and MoCA.
Conclusions:
- Statin use may have a protective effect on cognitive function in individuals with Parkinson's disease.
- Further research is warranted to elucidate the mechanisms underlying the cognitive benefits of statins in PD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
716
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
716
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
299
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
299
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K